Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC)
Enrolling By Invitation
18-99 years
Female
Phase
2
1 Location
Brief description of study
This phase II trial studies how well avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patients immune system.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 99 Years
-
Gender: Female
Updated on
01 Aug 2024.
Study ID: 834891
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
